Keyphrases
Therapeutic Strategies
100%
Glioblastoma
100%
PARP Inhibitor (PARPi)
100%
Rational Therapeutics
100%
Glioblastoma Cells
60%
BET Inhibitor
60%
Replication Stress
40%
Adverse Effects
20%
In Vitro Experiment
20%
Monotherapy
20%
DNA Damage
20%
Homologous Recombination Repair
20%
Cell Cycle Progression
20%
Zebrafish
20%
Glial Cells
20%
Nude Mice
20%
Innovative Drugs
20%
Reduced Toxicity
20%
Antitumor Efficacy
20%
Glioblastoma Therapy
20%
Glioblastoma Cell Lines
20%
Concurrent Administration
20%
Patient-derived
20%
Drug Administration
20%
Sequential Administration
20%
Concurrent Treatment
20%
Transcriptome Sequencing
20%
Primary Glioblastoma
20%
BET Inhibition
20%
Proteomic Sequencing
20%
DNA Cell Cycle
20%
DNA Replication Cycle
20%
Sequential Regimen
20%
Orthotopic Transplantation Tumor
20%
DNA Toxicity
20%
Immunology and Microbiology
DNA Damage
100%
Recombination Repair
100%
DNA Replication
100%
Nude Mouse
100%
Cell Cycle Progression
100%
Zebra Fish
100%
Homologous Recombination
100%
Transcriptomics
100%
Glioblastoma Cell Line
100%
Medicine and Dentistry
Glioblastoma
100%
Poly ADP Ribose Polymerase
100%
PARP Inhibitor
71%
Bromodomain Inhibitor
42%
In Vitro
14%
Adverse Event
14%
Neoplasm
14%
Monotherapy
14%
Glial Cells
14%
Drug Administration
14%
Recombination Repair
14%
DNA Damage
14%
Orthotopic Transplantation
14%
DNA Replication
14%
Homologous Recombination
14%
Transcriptomics
14%
Proteomics
14%
Cell Cycle Progression
14%
Glioblastoma Cell Line
14%
Birabresib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
62%
Bromodomain Inhibitor
37%
Neoplasm
12%
Adverse Event
12%
Monotherapy
12%
Nude Mouse
12%
Drug Administration
12%
Zebra Fish
12%
Birabresib
12%